DUBLIN--(BUSINESS WIRE)--Aug 24, 2018--The "Benign Prostatic Hyperplasia Therapeutics Market by Therapeutic Class, and Therapy - Global Opportunity Analysis and Industry Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.

The global benign prostatic hyperplasia therapeutics market was valued at $10,688.72 million in 2017, and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025.

This market is majorly driven by an increase in the male geriatric population because the disease generally occurs in men of age 60 and above. The other factors boosting the market growth include growth in awareness related to urological disorders and prostate cancer and rise in the number of global benign prostatic hyperplasia patients.

Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.

However, preferences for minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hinder the growth of the global BPH therapeutics market.

List of Key Players Profiled

Abbott Laboratories Allergan PLC Astellas Pharma Inc. Boehringer Ingelheim Pharma GmbH & Co. KG Eli Lilly and Company GlaxoSmithKline PLC Merck & Co. Inc. Pfizer Inc. Sanofi Teva Pharmaceutical Industries Limited

Key Topics Covered

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Market Overview

Chapter 4: Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutic Class

Chapter 5: Benign Prostatic Hyperplasia Therapeutics Market, by Therapy

Chapter 6: Benign Prostatic Hyperplasia Therapeutics Market, by Region

Chapter 7: Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/hcsnvd/opportunity?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180824005086/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Prostate Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/24/2018 04:57 AM/DISC: 08/24/2018 04:57 AM